Sang Yun Ha1, Juyoun Shin2, Jeong Hoon Kim3, Myung Soo Kang3, Hae-Yong Yoo3, Hyeon-Ho Kim3, Sung-Hee Um4, Seok-Hyung Kim5. 1. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 2. Division of Cancer Biology, Comparative Biomedicine Research Branch, Research Institute of National Cancer Center, Goyang, Korea. 3. Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea Department of Health Sciences and Technology, Sungkyunkwan University School of Medicine, Seoul, Korea. 4. Department of Cell Biology, Sungkyunkwan University School of Medicine, Suwon, Korea. 5. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea Department of Health Sciences and Technology, Sungkyunkwan University School of Medicine, Seoul, Korea.
Abstract
AIMS: Integrin αv subunits are involved in tumour angiogenesis and tumour progression in various types of cancers. Clinical trials evaluating agents targeting integrin αv are ongoing. Integrin αv expression has been reported in several cancers in association with tumour progression or poor survival. However, no study has addressed the prognostic influence of integrin αv expression on survival of patients with colorectal cancer (CRC). METHODS: Immunohistochemical staining of integrin αv was performed in 198 CRC samples to evaluate its prognostic significance. RESULTS: High expression of integrin αv was observed in 58.1% (115/189) of colorectal adenocarcinoma samples, while only in 11.5% (3/26) of tubular adenoma samples and in none of normal mucosa or hyperplastic polyp samples. It was more frequently found in female patients and less frequently observed in well differentiated tumours. The proportion of cases with high expression of integrin αv showed an increasing trend with increased T stage (p=0.032), N stage (p=0.006) and TNM stage (p=0.001). Patients displaying exuberant expression of integrin αv showed shorter overall survival (p=0.001) and disease-free survival (p=0.004). Elevated integrin αv expression was an independent prognostic factor for overall survival (HR: 2.04, 95% CI 1.16 to 3.56; p=0.013) and disease-free survival (HR: 2.19, 95% CI 1.16 to 4.13; p=0.015). CONCLUSIONS: Overexpression of integrin αv is associated with advanced T and N stage and as an independent prognostic factor in CRC. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
AIMS: Integrin αv subunits are involved in tumour angiogenesis and tumour progression in various types of cancers. Clinical trials evaluating agents targeting integrin αv are ongoing. Integrin αv expression has been reported in several cancers in association with tumour progression or poor survival. However, no study has addressed the prognostic influence of integrin αv expression on survival of patients with colorectal cancer (CRC). METHODS: Immunohistochemical staining of integrin αv was performed in 198 CRC samples to evaluate its prognostic significance. RESULTS: High expression of integrin αv was observed in 58.1% (115/189) of colorectal adenocarcinoma samples, while only in 11.5% (3/26) of tubular adenoma samples and in none of normal mucosa or hyperplastic polyp samples. It was more frequently found in female patients and less frequently observed in well differentiated tumours. The proportion of cases with high expression of integrin αv showed an increasing trend with increased T stage (p=0.032), N stage (p=0.006) and TNM stage (p=0.001). Patients displaying exuberant expression of integrin αv showed shorter overall survival (p=0.001) and disease-free survival (p=0.004). Elevated integrin αv expression was an independent prognostic factor for overall survival (HR: 2.04, 95% CI 1.16 to 3.56; p=0.013) and disease-free survival (HR: 2.19, 95% CI 1.16 to 4.13; p=0.015). CONCLUSIONS: Overexpression of integrin αv is associated with advanced T and N stage and as an independent prognostic factor in CRC. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: J Wang; B Zhang; H Wu; J Cai; X Sui; Y Wang; H Li; Y Qiu; T Wang; Z Chen; Q Zhu; H Xia; W Song; A P Xiang Journal: Oncogene Date: 2016-09-05 Impact factor: 9.867
Authors: Christine Böger; Viktoria S Warneke; Hans-Michael Behrens; Holger Kalthoff; Simon L Goodman; Thomas Becker; Christoph Röcken Journal: Gastric Cancer Date: 2014-10-15 Impact factor: 7.370
Authors: Diana J Uribe; Edward K Mandell; Adam Watson; Jesse D Martinez; Jonathan A Leighton; Sourav Ghosh; Carla V Rothlin Journal: PLoS One Date: 2017-07-20 Impact factor: 3.240